Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study


23 Nov 2019


Poster display session


Tumour Site

Breast Cancer


Nisha Hariharan


Annals of Oncology (2019) 30 (suppl_9): ix9-ix12. 10.1093/annonc/mdz417


N. Hariharan1, T..S. Rao2, S. Rajappa3, C..C..K. Naidu1, K..V..V..N. Raju2, V. Koppula4, R. Sudhir4, S. Murthy5, S. Kodandapani5, D. Fonseca5

Author affiliations

  • 1 Breast Oncosurgery, Basavatarakam Indo American Cancer Hospital & Research Institute, 500034 - Hyderabad/IN
  • 2 Surgical Oncology Department, Basavatarakam Indo American Cancer Hospital & Research Institute, 500034 - Hyderabad/IN
  • 3 Medical Oncology, 2. Basavatkaram Indo American Cancer Hospital, 500034 - Hyderabad/IN
  • 4 Radiology, Basavatarakam Indo American Cancer Hospital & Research Institute, 500034 - Hyderabad/IN
  • 5 Pathology, Basavatarakam Indo American Cancer Hospital & Research Institute, 500034 - Hyderabad/IN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 28P


With the advent of taxanes and targeted agents in neoadjuvant chemotherapy (NACT) for breast cancer, the rates of pathologic complete response (pCR) have been steadily increasing. One of the roles of surgery in these women is to serve the purpose of a biopsy to confirm or negate a pCR.


We conducted a prospective validation study. Women who had undergone a titanium clip placement followed by neoadjuvant chemotherapy (NACT), and achieved a complete/near complete clinical and radiological response were included. Eligible women underwent an MRI of the breast followed by a US guided core biopsy (CNB) of the tumour bed. The CNB was compared with the final histopathology report after definitive surgery.


65 patients were recruited in this study, of whom 75% had T1/2 tumours and 39 women had hormone negative tumours. The overall rate of pCR in the breast (BrpCR) was 42%. Among women with BrpCR, only one patient had residual disease in the axilla (macrometastasis). The mean number of CNB of the tumour bed after NACT was 4. The accuracy of CNB in predicting BrpCR was 69%, with a false negative rate (FNR) of 14.8%. In a pre-planned sub-group analysis of hormone negative tumours, the FNR was 9.5%. No untoward side effects were observed in any of the patients.


Ultrasound guided CNB of the tumor bed was useful in predicting BrpCR, especially in hormone negative tumours, with an FNR of 9.5%. Increasing the number of cores in the biopsy or changing the imaging modality could help in improving the accuracy of this method.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Hyderabad Cancer Foundation.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.